Five-year safety and efficacy of belatacept in renal transplantation

F Vincenti, G Blancho, A Durrbach… - Journal of the …, 2010 - journals.lww.com
Belatacept is a first-in-class co-stimulation blocker in development for primary maintenance
immunosuppression. A Phase II study comparing belatacept with cyclosporine (CsA) for
prevention of acute rejection and protection of renal function in kidney transplant recipients
demonstrated similar efficacy and significantly higher measured GFR at 1 year for
belatacept, but the incidence of posttransplantation lymphoproliferative disorder was higher.
Here, we present the results for the extension of this trial, which aimed to assess long-term …